Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in Residual β-cell Function and Inflammatory Markers in New-onset Type 1 Diabetes Mellitus.

NCT01559025 is registered in ClinicalTrials.gov with Federal University of São Paulo as lead sponsor.

NCT NCT01559025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01559025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in Residual β-cell Function and Inflammatory Markers in New-onset Type 1 Diabetes Mellitus.
Lead sponsor
Federal University of São Paulo
Phase
Phase 3
Overall status
Unknown status
Start date
March 31, 2014
Completion date
March 31, 2017
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diabetes, insulin dependent diabetes, juvenile onset diabetes mellitus, type 1 diabetes